Medical assessment from the manufacturer noted that all patients presenting with grade 3 adverse events received sequential bilobar treatment, and commented on the infrequent rate of reported grade 3 adverse events (3 out of 32 patients).Reild, pain and worsening liver function are all anticipated adverse events associated with the use of therasphere.The medical assessment concurred with the reporter's assessment of the radioembolization-induced liver disease (reild) that resulted in the patients death.The medical assessment noted that the event was likely caused from a combination of receiving therasphere to the whole liver, along with any chemotherapy the patient had received prior to therasphere treatment.
|